Live Patient Cases to be Supported by BioSig’s PURE EP System During EPLive 2020

BioSig Technologies (NASDAQ: BSGM) is a medical technology company which designs and commercializes an innovative signal processing platform. Bio Sig’s signal processing platform is aimed to uncover the full range of ECG and intra-cardiac signals and to improve signal fidelity.

BioSig Technologies has recently announced that during EPLive 2020, the fifth international symposium on complex arrhythmias, its first product, the PURE EP system, would be featured in several live cases broadcast.

Medical Device Manufacturing

In recent years, the medical device industry has grown steadily, driven by global technological advances, the digitization and incorporation of new technologies, the increasing demand by the population, placing the sector in a complete panorama of growth and development.

Today, different companies manufacture devices capable of measuring the heart rate, pressure, sugar levels and the general state of the patient's health in an easy and affordable way for the population. New information technologies allow real-time diagnostics and automate health measurements, reliably and at the patient's hand at home.

The Undiscovered Potential of Bioelectronic Medicine

Bioelectronic Medicine is a new field of medicine that combines neuroscience, molecular biology and bioengineering to delve into the nervous system to treat disease and injury without the use of drugs. Bioelectronic Medicine promises to bring new insights into the diagnosis and treatment of diseases and conditions as varied as cancer, rheumatoid arthritis, inflammatory bowel disease, obesity, diabetes, asthma, paralysis, blindness, bleeding, ischemia, organ transplantation, cardiovascular disease, neurodegenerative diseases, and others.

Bioelectronics is a relatively new branch of healthcare, which, as the name suggests, focuses on the nexus of electronics and biological research. The term can encompass a number of different therapies, but BioSig’s main focus is on creating develop and deliver the advanced signal processing solutions that will unlock the future of bioelectronic medicine, starting with the PURE EP™ System. Namely, this Westport-based medical device company is developing a proprietary biomedical signal-processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace.

“Bioelectronic medicine has the potential to transform healthcare throughout the coming decades, much like we’ve seen with the biotech revolution. But the first order of business for those active in the field is to develop a collective vision for how these technologies can improve lives – a vision that other stakeholders can understand and act on,” says Ken Londoner, founder, CEO, and chairman, BioSig Technologies. Since its founding in 2009, BioSig Technologies has been working hard to lead one of the most innovative and most promising frontiers in healthcare. In order to achieve that, BioSig is now ready to commercialize the company’s first product: the PURE EP™ System. Looking further ahead, BioSig expects to publish trial results, grow internationally, and expand their product pipeline.

In 2018, BioSig received FDA 510(k) clearance for PURE EP™, began market launch, and BioSig was uplisted to the NASDAQ national exchange. BioSig Technologies (BSGM) has a market capitalization of $82.52M. Recently BSGM recorded volume of 210046 shares in most recent trading session as compared to an average volume of 185.63K shares. It shows that the shares were traded in the recent trading session and traders shown interest in BSGM stock.